| Keywords: |
adult; cancer chemotherapy; clinical article; aged; drug efficacy; phase 2 clinical trial; breast; mucosa inflammation; nausea; vomiting; inflammation; breast neoplasms; gastrointestinal toxicity; drug dose; drug therapy; adverse drug reaction; therapy; aminopterin; intravenous drug administration; mucous membrane; middle age; bone marrow depression; drug evaluation; 10 deazaaminopterin; intoxication; human; priority journal; support, u.s. gov't, p.h.s.; deazaaminopterin; blood and hemopoietic system
|
